(0.23%) 5 111.55 points
(0.20%) 38 315 points
(0.24%) 15 966 points
(-1.42%) $82.66
(3.90%) $1.998
(0.06%) $2 348.50
(-0.24%) $27.47
(3.56%) $954.95
(-0.19%) $0.933
(-0.34%) $10.99
(-0.45%) $0.797
(1.71%) $93.44
@ $21.84
发出时间: 15 Feb 2024 @ 04:27
回报率: 0.14%
上一信号: Feb 10 - 02:56
上一信号:
回报率: -3.36 %
Live Chart Being Loaded With Signals
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications...
Stats | |
---|---|
今日成交量 | 47 314.00 |
平均成交量 | 237 943 |
市值 | 1.02B |
EPS | $0 ( 2024-03-13 ) |
下一个收益日期 | ( $-0.230 ) 2024-05-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -15.08 |
ATR14 | $0.0770 (0.35%) |
音量 相关性
Silence Therapeutics plc 相关性 - 货币/商品
Silence Therapeutics plc 财务报表
Annual | 2023 |
营收: | $25.38M |
毛利润: | $15.06M (59.34 %) |
EPS: | $-1.170 |
FY | 2023 |
营收: | $25.38M |
毛利润: | $15.06M (59.34 %) |
EPS: | $-1.170 |
FY | 2022 |
营收: | $17.50M |
毛利润: | $6.62M (37.83 %) |
EPS: | $-1.260 |
FY | 2021 |
营收: | $12.42M |
毛利润: | $4.96M (39.94 %) |
EPS: | $-1.329 |
Financial Reports:
No articles found.
Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。